A landmark study involving researchers from across Africa has identified new genetic variants that increase the risk of chronic kidney disease in continental African populations, marking a major advance in medical genomics and challenging assumptions that have shaped research for decades. The study, conducted by the KidneyGenAfrica consortium and involving more than 26,000 individuals from eastern, western, and southern Africa, is the largest genetic investigation of kidney function ever undertaken on the continent.
The findings, published in the journal Nature Communications, reveal four genetic locations associated with reduced kidney function in continental Africans — two of which had never been previously documented. When combined with data from African diaspora populations in North America and Europe, the study identified 19 genetic locations, three of which were novel discoveries. Each of these represents a potential target for future drug development or diagnostic innovation.
The Burden of Kidney Disease in Africa
Chronic kidney disease is one of the fastest-growing causes of death globally, affecting approximately 850 million people worldwide — more than the combined number of people living with diabetes and cancer. In sub-Saharan Africa, the burden is particularly severe, driven by high rates of hypertension, type 2 diabetes, and other risk factors that damage the kidneys over time. Around 30 percent of adults in the region have high blood pressure, and an estimated 25 million adults have diabetes, most of it undiagnosed and untreated.
Africa as a whole has fewer than one nephrologist per million people, compared with a global median of approximately 10 per million. In high-income countries, that figure climbs to 23 per million. For the vast majority of Africans who develop kidney failure, treatment options are extremely limited or entirely unavailable.
The APOL1 Gene: A Transatlantic Surprise
One of the study’s most striking findings concerns the APOL1 gene, which has been extensively studied in African-American populations. Two variants of this gene — known as G1 and G2 — were already known to increase the risk of severe kidney disease by as much as threefold in people of African descent living in the United States. The assumption, widely held in the medical literature, was that the same variants would have similar effects on people living in Africa.
However, the new data shows that the reality is far more complex. The high-risk APOL1 variants occur at lower frequencies across different regions of Africa, and their association with reduced kidney function is substantially weaker in continental African populations than in the diaspora. Put simply: the same gene appears to behave differently depending on where a person lives and which population they belong to.
This finding carries major implications for drug development. Clinical trials of kidney disease treatments must now be designed to include continental African populations, not just people of African descent in Western countries, if the resulting therapies are to be genuinely effective across the full spectrum of those at risk.
The Importance of African Genomic Data
The study underscores a long-standing gap in global genomic research. Africa, home to the most genetically diverse human populations on Earth, has historically been underrepresented in the research that shapes worldwide medical understanding. The KidneyGenAfrica consortium represents a deliberate effort to correct that imbalance, building research capacity on the continent while simultaneously generating data of direct benefit to African populations.
Researchers also developed and tested polygenic risk scores — tools that estimate an individual’s overall genetic susceptibility to kidney disease. They found that scores built using data from genetically similar African populations performed better than those derived from larger but genetically distant datasets. This highlights a fundamental truth in precision medicine: the science only works when the reference data reflects the population it is meant to serve.
What Must Follow
Researchers say the findings must now translate into concrete changes in public health policy across Africa. African health systems need to invest in early kidney disease detection — simple, affordable blood and urine tests can identify kidney damage at a stage when lifestyle interventions and medications can still make a meaningful difference. Genetic risk tools could help prioritize screening for those most at risk, making the most of limited clinical resources.
Pharmaceutical companies, meanwhile, face increasing pressure to include African participants in their clinical trials. The global research community must continue building genomic infrastructure on the continent — creating cohorts of consenting participants whose genetic and health data can be studied for generations to come.
This research demonstrates that African scientists, working in partnership with their own communities, can produce knowledge that reshapes the global understanding of disease. The world’s approach to one of its most urgent health challenges will be sharper for it — but only if the investment in African science continues to grow.